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Lymphoproliferative responses (LPRs) to recall antigens (Ags) and human immunodefi-
ciency virus type 1 (HIV-1) Gag and frequencies of circulating HIV-1–specific cytotoxic T
lymphocyte precursors (CTLps) were measured in 12 patients undergoing highly active an-
tiretroviral therapy (HAART) after long-standing HIV-1 infection. LPRs to at least 1 recall
Ag became detectable or increased in all patients during HAART. No significant LPRs to
Gag-p24 were observed, whereas 4 of 8 patients tested presented with Gag-p17–specific LPRs.
HIV-1–specific CTLp frequencies became measurable or increased early during therapy in 6
of 10 patients tested and were maintained or decreased thereafter. Increasing HIV-1–specific
CTLp frequencies were seen only in association with partial HAART failure in 1 patient. In
conclusion, restoration of CD4+ T lymphocyte responsiveness to recall Ags is achieved during
HAART. The data provide evidence for limited HIV-1–specific CD4+ memory T cells during
advanced HIV-1 infection and suggest that both CD4+ and CD8+ HIV-1–specific T cells are
poorly stimulated when viral load is suppressed.
Current antiretroviral therapy (ART) has greatly modified
the poor prognosis of human immunodeficiency virus type 1
(HIV-1) infection. Treatment with combinations of drugs that
block two crucial steps of the virus’s life cycle, reverse tran-
scription and protein cleavage, is commonly referred to as
highly active ART (HAART). These powerful treatment regi-
mens can reduce viral load both in the circulation and in lym-
phoid tissue and significantly increase circulating CD41 T cell
numbers [1–4]. Successful HAART is thus likely to achieve viral
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latency, although virus persists in reservoirs [5, 6]. From this
perspective, irreversible damage induced during untreated HIV-
1 infection and the occurrence of viral resistance or drug toxicity
may determine the survival of treated patients. It is, therefore,
of great clinical importance to establish whether the recently
available regimens of HAART achieve functional immune
recovery that confers protection from late infectious
complications.
Moreover, assuming that a functional immune system is also
effective in limiting HIV-1 replication and spread, it is reason-
able to speculate that improvement of T cell immunity might
be an additional factor involved in the control of HIV-1 during
therapy. In this view, the combination of HIV-1–specific im-
munotherapy and HAART has been proposed to maximally
exploit the amelioration of immune conditions and overcome
the paucity of viral antigen (Ag) occurring during therapy [7].
Initial interpretations of the transient increase in CD41 T
cell number observed during monotherapy with a protease in-
hibitor suggested that the natural T cell homeostasis was re-
established and that lymphocytes were driven to proliferate
toward normal levels [8, 9]. Transient functional improvement
was also detected in lymphocyte responses to mitogens and Ags,
but the short duration of drug effect on viral load halted any
significant benefit to the treated patients [10]. The analysis of
patients experiencing persistent viral load reduction because of
effective drug combinations revealed a different scenario. Early
lymphocyte repopulation appears to be caused mostly by rapid
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Table 1. Characteristics of patients selected from study NUCB2019 at entry.
Study no.
Age
(years) CDCa Treatmentb Pre-HAART illnesses
T cell functionc
CD41 T cells
(cells/mL)
CD3
(%)
PHA
(%)
HIV-1 RNA
(log10 copies/mL)
20492 43 A Imm. Crohn’s disease 403 20 73 4.59
20444 43 B Imm. Diarrhea 11 month 323 23 19 5.10
20478 50 B Del. Diarrhea 11 month 270 2 3 5.03
20484 38 B Imm. Oral candidosis 137 3 7 6.09
20506 28 C Imm. Toxoplasmosis, oral candidosis 93 16 46 5.89
20482 34 A Del. None 80 3 7 5.41
20489 30 C Del. Tuberculosis, multidermatomal zoster 57 1 1 5.42
20490 40 B Imm. Oral candidosis 40 3 6 6.36
NOTE. HAART, highly active antiretroviral therapy; HIV-1, human immunodeficiency virus type 1.
a 1993 Centers for Disease Control (CDC) classification [24].
b Imm., simultaneous start of 3 drug administration; del., lamivudine and zidovudine were added after 3 weeks of ritonavir monotherapy.
c T cell reactivity to CD3 monoclonal antibody and phytohemagglutinin (PHA) expressed as % of controls.
recirculation of CD41 T cells, predominantly of the memory
phenotype [11, 12], that show little degree of proliferation, as
assessed by the expression of cell cycle–associated Ki-67 nuclear
Ag [13]. Preliminary observations suggested that, nonetheless,
memory T cell function, measured as in vitro lymphoprolifer-
ative responses (LPRs) to mycobacterial and cytomegalovirus
(CMV) Ags, barely detectable before therapy, was at least par-
tially restored [11].
To establish the degree and persistence of putatively protec-
tive immunity and the potential immune control on HIV-1 itself,
we combined the analysis of T cell responses to recall and
microbial Ags and to HIV-1 Ags in patients with moderately
advanced HIV-1 infection who were undergoing HAART. The
appearance of stable recall LPRs comparable with those de-
tected in retrospective samples from an earlier, asymptomatic
state and the detection of moderate, often transient, HIV-1–
specific cytotoxic T lymphocyte (CTL) responses in some
treated patients are the major findings reported and discussed
here.
Materials and Methods
Patients and treatment. Twelve patients naive for ART were
selected on the basis of HIV-1 plasma viremia reduction 12.5 log
RNA copies/mL upon initiation of ART. Eight of them participated
in the NUCB2019 study [4] and received either immediate triple
therapy—a combination of ritonavir (600 mg 23/day), lamivudine
(3TC; 150 mg 23/day), and zidovudine (ZDV; 300 mg 23/day)—or
ritonavir alone for 3 weeks and then the triple combination (delayed
triple therapy). The remaining 4 patients were chosen among HIV-
1–infected homosexual men participating in the Amsterdam Cohort
(ACH) studies on HIV infection and AIDS [14] to compare immune
responses in samples obtained during long-term follow-up of
asymptomatic infection with those measured during HAART. One
of the ACH patients (1095) participated in the NUCB2019 study
under code 20472, and the remaining patients initially received a
combination of 3TC (150 mg 23/day) and stavudine (d4T; 40 mg
23/day) or ZDV (200 mg 33/day); indinavir (800 mg 33/day) was
added when plasma viremia exceeded the value of 500 copies/mL
[15].
Plasma viremia. Plasma HIV-1 RNA levels were measured by
use of a commercial quantitative reverse transcriptase (RT) poly-
merase chain reaction kit (Amplicor HIV Monitor Test; Roche
Molecular Systems, Branchburg, NJ) with an average lower de-
tection level of 2.4 log10 copies/mL or, for most pretherapy retro-
spective determinations, by use of a nucleic acid sequence–based
amplification assay (NASBA HIV-1 RNA QT; Organon Teknika,
Boxtel, The Netherlands) with a lower detection limit of 103 copies/
mL of serum.
In vitro lymphocyte proliferation assays. In vitro T cell reac-
tivity to mitogens was measured in fresh whole blood lymphocyte
cultures as previously described [16]. Briefly, 1:10 diluted hepa-
rinized venous blood was cultured in 3 replicate wells of round-
bottom microtiter plates in the presence of CD3 monoclonal an-
tibody (mAb) or phytohemagglutinin (PHA). LPR was measured
after 4 days by [3H]-thymidine incorporation. T cell reactivity was
expressed as counts per minute (cpm). Samples from 5 healthy HIV-
1–negative blood donors were included in each assay as controls.
Results were expressed as a percentage of the mean T cell reactivity
of controls.
As previously described [17], Ag-specific LPRs were measured
retrospectively, culturing 105 thawed peripheral blood mononuclear
cells (PBMC) in 3–6 replicate round-bottom microtiter wells for 7
days in 0.1 mL of RPMI-1640 supplemented with antibiotics and
10% human pooled serum in the presence of one of the following
Ags: (1) Candida albicans type A mannan-depleted broken yeast
Ags (Accurate, Westbury, NY), extensively dialysed (1:100 final
dilution); (2) tetanus toxoid (TT; RIVM, Bilthoven, The Nether-
lands), final concentration 30 Lf/mL; (3) Mycobacterium tubercu-
losis purified protein derivative (PPD; Statens Serum Institute,
Copenhagen, Denmark), final concentration 10 mg/mL; or (4) Es-
cherichia coli–expressed recombinant Gag-p24 and Gag-p17 of
HIV-1 (British Biotech Pharmaceutical Ltd., Oxford, United King-
dom), final concentration 6 mg/mL. [3H]-thymidine (specific activity,
5 mCi/mmol) was added for the last 20 h of culture, and the in-
corporated radioactivity was measured in a b-scintillation counter.
Results were expressed as net cpm, that is, the difference between
median cpm in the Ag-containing cultures and median cpm in
cultures in medium alone, and as stimulation index (LSI), that is,
the ratio between median cpm in the Ag-containing cultures and
median cpm in cultures in medium alone. Positive LPRs were
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Figure 1. A, CD41 T cell numbers and B, human immunodeficiency virus type 1 (HIV-1) RNA plasma load measured at the time of T cell
response assessment in 8 patients enrolled in the NUCB2019 study [4] of triple drug combination (ritonavir, lamivudine, and zidovudine). See
patients’ characteristics at study entry in table 1.
scored when both net cpms were 12 SD from the mean of unsti-
mulated PBMC cultures (280 cpm) and the LSI was 13.
HIV-1–specific CTL responses. Recombinant vaccinia viruses
(rVVs) TG.1144 [18] and TG.4163 [19], which express HIV-1LAI gag
and HIV-1LAI RT, respectively, were kindly provided by Dr. Y. Ri-
vie`re (Institut Pasteur, Paris, France) and Dr. M. P. Kieny (Trans-
ge`ne S.A., Strasbourg, France). Vaccinia virus 186poly containing
no insert was used as a control. HIV-1–specific CTL precursors
(CTLps) were expanded in vitro by Ag-specific stimulation as pre-
viously described [20–22]. Frequencies of CTLps specific for each
HIV-1 product were determined by use of standard methods of
limiting dilution analysis [23]. Briefly, PBMC were thawed and
resuspended in RPMI-1640 supplemented with antibiotics and 10%
pooled human serum. Eight serial dilutions, ranging from 246 to
26,000 PBMC/well, were seeded in 24 replicate wells in 96-well
round-bottom microtiter plates. Stimulator cells were autologous
Epstein-Barr virus–transformed B-lymphoblastoid cell lines (B-
LCLs) infected with rVVs expressing the individual HIV-1 gene
products and subsequently fixed with paraformaldehyde. To each
well, 104 fixed stimulator cells and an equal number of irradiated
feeder cells were added. Feeder cells were previously generated by
Leucoagglutinin A (Sigma Chemicals, St. Louis) stimulation of
autologous cryopreserved PBMC. Microcultures were maintained
for 15 days at 37oC and 5% CO2. At days 2 and 9, cultures were
fed with medium containing human recombinant interleukin
(rIL)–2 (360 IU/mL final concentration, kindly provided by Dr. R.
Rombouts; Chiron Benelux, Amsterdam), and on day 7 they were
restimulated with 104 fixed stimulator cells and rIL-2. On day 15,
wells were split, and effector cells were tested for cytotoxicity in a
standard 51chromium-release assay with autologous B-LCLs in-
fected with each HIV-1 gene product–expressing rVV separately or
with 186poly. Specific lysis was calculated with the formula
(experimental release minus spontaneous release)/(maxi-100 3 [
mum release minus spontaneous release)]. Wells were considered
positive when the 51Cr release exceeded 10% specific lysis. CTLp
frequencies were expressed as the number of CTLps/106 PBMC.
HIV-1–specific CTLp frequencies were computed as differences be-
tween CTLp frequencies determined with HIV-1 gene-expressing
rVV-infected targets and those determined with control targets.
Statistical analysis. Comparison of paired data from patients
at different times of follow-up was performed by Wilcoxon’s signed
rank test.
Results
Immune reconstitution during HAART. A group of 8 pa-
tients enrolled in the NUCB2019 study was selected on the basis
of viral load reduction 12.5 log HIV-1 RNA copies/mL per-
sisting for up to 9 months from start of therapy. Baseline CD41
T cell numbers, plasma viremia levels, and T cell reactivity to
PHA and CD3 mAb are reported in table 1. Immune para-
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Figure 2. Lymphoproliferative response (LPR) to recall antigens before and during 9 months of highly active antiretroviral therapy in 8 patients
enrolled in the NUCB2019 study [4]. Results are expressed as net counts per minute (cpm). Horizontal dashed lines represent 2 SD from the
mean cpm in unstimulated cultures, taken as assay detection limit. TT, tetanus toxoid; PPD, purified protein derivative.
meters were analyzed in samples collected during the 2 weeks
preceding HAART administration (t0) and, on average, after
5 weeks (month 1), 21 weeks (month 4), and 41 weeks (month
9) of therapy. As shown in figure 1, all patients showed an
increase in CD41 T cell numbers 1100 cells/mL, together with
rapid decline of plasma viremia, approaching undetectable lev-
els after 1 month of therapy and remaining below or occa-
sionally just above the assay quantification limit thereafter.
We studied responses to Candida Ags as a typical and com-
mon opportunistic agent, TT as a prototypic vaccine Ag un-
likely to be encountered during the follow-up, and M. tuber-
culosis PPD as an example of a pathogen. The responses,
measured in cultures of thawed PBMC from each patient, are
shown in figure 2. Before HAART was begun, measurable
LPRs to Candida were found in the 2 patients with the highest
baseline CD41 T cell counts. During therapy, LPRs to Candida
were detected in 5 patients. Among them, the 2 patients with
pre-HAART Candida-specific responses showed increased re-
sponses during therapy. In a paired-data statistical analysis, a
significant difference in comparison with baseline values of
LPRs to Candida was found at week 21 ( ) but not atP 5 .018
week 41, when LPRs in 3 of the 5 responders were no longer
detectable or were greatly reduced. Responses to TT followed
a similar pattern, being barely detectable in only 1 patient be-
fore therapy and increasing from week 5 of therapy to reach
statistically significant difference from baseline values at week
21 ( ). In total, 5 patients showed improved LPRs toP 5 .043
TT during HAART, together with improved responses to Can-
dida in 3. As for Candida Ags, such responses were no longer
detectable in 2 patients at week 41. LPRs to PPD, totally un-
detectable before therapy, were seen in 4 patients during
HAART and were significantly different from baseline values
only at week 41 ( ). Only patient 20489, who had aP 5 .018
history of active tuberculosis, showed vigorous PPD-specific
LPRs starting from week 5 onwards. Appearance of LPR to
at least 1 recall Ag was seen in all 8 patients during HAART
and appearance of LPR to at least 2 of the 3 Ags tested in 5
patients. A more detailed description of LPRs and immune
parameters in 4 of these patients is included in a separate report
[25].
HIV-1–specific T cell responses. As representative of HIV-
1–specific CD41 T lymphocyte responses, the LPR to recom-
binant HIV-1–Gag proteins was measured. As shown in figure
3A, no p24-specific LPRs were detected before HAART, and
only 1 patient (20444) showed a significant response (LSI 5
) at week 21. LPRs specific to p17 were also undetectable4.7
before HAART and appeared in 4 patients, at either week 5
or 21, with LSIs of 4.1–5.9 (figure 3B).
HIV-1–specific CTLp frequencies were measured in the 6
patients included in the study for whom B-LCL could be es-
tablished (figure 4). HIV-1–Gag and RT were chosen as rep-
resentative specificities, given the results of our previous lon-
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Figure 3. Lymphoproliferative response (LPR) to human immunodeficiency virus type 1 Gag-p24 (A)and Gag-p17 (B), expressed as net counts
per minute (cpm), before and during 9 months of highly active antitretroviral therapy in 8 patients enrolled in the NUCB2019 study [4]. Horizontal
dashed lines represent the assay detection limit.
gitudinal evaluation [22]. In that study, Gag- and RT-specific
CTLps were the most abundant and were detected in all pa-
tients, representing a suitable parameter to evaluate specific T
cell function. No CTL activity was detected in pretherapy sam-
ples. Although a statistically significant difference with baseline
values was not reached, Gag-specific CTLp frequencies ranging
from 23 to 80 CTLps/106 PBMC were found in 3 patients at
weeks 5 and 21, in association with detectable RT-specific CTL
activity in 2 (13–29 CTLps/106 PBMC). Only 1 patient (20478)
had detectable HIV-1–specific CTLps, against both Gag- and
RT-expressing targets, in PBMC obtained after 9 months of
therapy.
Longitudinal analysis of T cell responses during untreated
asymptomatic HIV-1 infection and during treatment. To es-
tablish the degree of T lymphocyte reconstitution obtained dur-
ing therapy, retrospective PBMC samples from 4 patients en-
rolled in the Amsterdam Cohort of homosexual men were
studied, and recall Ag- and HIV-1–specific responses during
therapy were compared with those measured during untreated
infection with limited immune impairment. CD41 T cell num-
bers, viral load, recall Ag–specific LPRs, and HIV-1–specific
CTLp frequencies in these patients are shown in figure 5, up-
per–lower panels. All of these patients started therapy with
plasma viremia 15.5 log RNA copies/mL and reduced CD3
mAb T cell reactivity (!20% of that of controls in 3 of them
and !40% in patient ACH6085).
Patient ACH68 had relatively stable and elevated numbers
of circulating CD41 T cells that doubled with therapy. Inter-
estingly, this patient had undergone splenectomy as treatment
for thrombocytopenia several years before HAART. Immedi-
ately after splenectomy, a significant p24-specific LPR (LSI 5
) was detected. During HAART, the p24-specific LPR did6.6
not reach significant levels ( ), whereas the response toLSI ! 2
Candida increased, approaching the levels of early infection.
Gag-specific CTL activity, barely detectable before HAART,
did not increase thereafter. The patient had a diagnosis of non-
Hodgkin’s lymphoma after 3 months of dual therapy, and in-
dinavir was not added to the drug combination.
Patient ACH6085, who also started HAART with relatively
stable and preserved CD41 T cell counts, had an undetectable
LPR to TT, which could be measured immediately after
HAART commenced. Significant levels of CTL activity, mea-
sured before therapy, increased early during HAART and were
maintained almost unchanged during the subsequent follow-
up. In this patient, as well as in the 2 described below, no p24-
specific LPR was ever detected.
Patient ACH211, previously classified as a long-term survi-
vor because of asymptomatic infection for 19 years with con-
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Figure 4. Frequency of circulating cytotoxic T lymphoctye (CTL) precursors specific for (A) human immunodeficiency virus type 1–Gag and
(B) reverse transcriptase (RT) before and during 9 months of highly active antiretroviral therapy in 6 patients enrolled in the NUCB2019 study
[4]. Horizontal dashed lines represent the assay detection limit.
served CD41 T cell numbers, presented a steady decline of
CD41 T cells in the 3 years preceding HAART. Response to
Candida-specific LPR and HIV-1–specific CTL activity, quite
vigorous during early infection, was totally undetectable at start
of therapy, when CD3 mAb reactivity was also greatly reduced.
After 1 month of HAART, the response to Candida and CTL
activity was already restored to levels comparable with those
measured in samples from early infection and did not change
significantly during the follow-up.
Patient ACH1095 started HAART after a prolonged period
of reduced T cell responsiveness and a steady decline of CD41
T cell numbers. Candida-specific LPRs and HIV-1–specific CTL
activity were restored within the first month of therapy. This
patient showed a partial therapy failure, with increasing viral
load after 4 months of HAART. In association with the failure
in virus control, response to Candida was no longer detectable
in the last sample tested, and frequencies of HIV-1–specific CTL
increased during the follow-up.
Discussion
Functional recovery of T cells during drug-induced suppres-
sion of HIV-1 replication has been reported with respect to
responses to mitogens and microbial Ags [10–12]. We per-
formed simultaneous measurements of lymphocyte responses
to microbial and HIV-1 Ags to assess the relevance of improved
T cell function for HIV-1–specific T cell immunity. The data
presented here demonstrate that lymphocyte responses to recall
Ags substantially and persistently improved during HAART,
reaching levels comparable with those measured in the same
subjects during early or stable asymptomatic infection. This
suggests that at least partial protection against common op-
portunistic agents is achieved. Similarly, comparable frequen-
cies of CMV-specific CD41 T cells, as detected by a sensitive
assay based on early activation markers and flow cytometry,
were found both in untreated HIV-1–infected patients with no
history of CMV disease and in HAART-treated patients with
quiescent CMV disease. In contrast, lower frequencies of CMV-
specific CD41 T cells were detected in patients with active CMV
disease [26].
The relative decrease in responses to recall Ags in the late
samples of some patients included in the present study, however,
could be a sign of transient, although prolonged, effect on T
lymphocyte function despite a persistent reduction of viral load.
This finding deserves further characterization and could be ex-
plained alternatively by the dynamic changes in the T cell pop-
ulation. We recently reported that a reduction in T cell receptor
(TCR) repertoire diversity occurs initially during HAART [27]
in association with the phase of predominant repopulation by
T cells of the memory phenotype. This phenomenon could be
related to clonal expansion driven by Ags present at that time.
These expansions subside once the Ags are eliminated and the
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Figure 5. Impact of highly active antiretroviral therapy (ART) on T cell responses during long-standing human immunodeficiency virus type
1 (HIV-1) infection in 4 HIV-1–infected homosexual men participating in the Amsterdam Cohort. Upper panels depict the sum of Gag- and
reverse transcriptase–specific cytotoxic T lymphocyte precursor (CTLp) frequencies (V) and the lymphoproliferative responses to a representative
recall antigen, as specified (thick solid line). PBMC, peripheral blood mononuclear cells; TT, tetanus toxoid; 3TC, lamivudine; d4T, stavudine.
TCR diversity decreases, approaching normal distribution after
several months of HAART [27, 28]. Similarly, reconstitution of
pathogen-specific T cell immunity appears to induce patholog-
ical processes that are involved in the reaction to preexisting
microbes and that cause clinical manifestations referred to as
“immune restoration disease” [29]. In contrast, loss of control
on viral load despite no significant changes in the number of
circulating CD41 T cells, as observed in the follow-up of patient
ACH1095, may rapidly induce a deterioration of Ag-specific
responses. This mimics the early loss of responses to recall Ags
without the significant CD41 T cell depletion observed during
the natural history of HIV-1 infection [30].
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Figure 5. (continued) Lower panels depict CD41 T cell numbers (thick solid line) and HIV-1 RNA plasma load (V). PBMC, peripheral blood
mononuclear cells; 3TC, lamivudine; ZDV, zidovudine.
The detection of recall responses, conceivably in the absence
of the relevant Ags in vivo, as we can reasonably assume at
least for TT, suggests that immunological memory, and there-
fore the capacity to respond when the Ags are encountered
again, is restored. This is compatible with the evidence of mem-
ory cells recirculating after having been trapped in lymphoid
tissue [12]. Indeed, Li et al. have shown that recovery of recall
Ag responses was dependent upon a significant CD41 memory
T cell increase, together with a profound and sustained viral
load reduction, in a group of patients with low baseline CD41
T cell levels who were undergoing HAART [31]. However, ap-
pearance of, or increase in, recall Ag–specific responses in pa-
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tients with high numbers of circulating CD41 T cells who were
undergoing therapy (such as patients ACH6085, ACH68,
20492, and 20444), and who therefore had smaller recirculating
fractions [12], suggests that this mechanism may be only partly
responsible for the regained reactivity to Ags. As a possible
additional mechanism involved in the recovery of T cell func-
tion, decreased levels of proinflammatory cytokines due to viral
load reduction may both mobilize lymphocytes from tissues
and render them less susceptible to activation-induced apop-
tosis. A decrease in circulating tumor necrosis factor–a, known
to induce lymphocyte apoptosis and functional suppression
[32], was found during HAART in association with restored
delayed-type hypersensitivity responses [33].
In general, the data now available on reconstitution of mem-
ory T cell responses indicate that no substantial deletion of Ag-
specific CD41 T cells occurs during HIV-1 infection [34]. This
is apparently also the case when heavy exposure to the relevant
pathogen occurs, as suggested by the vigorous and early re-
sponses to Candida in patients 20484 and 20490 and to PPD
in patient 20478. This observation is in agreement with the
mentioned trend to normalization of the CD41 TCR repertoire
after 6 months of HAART [28].
T cell responses to HIV-1 antigens follow a different pattern.
Conceivably as a direct consequence of the recovery of T cell
function achieved in the early phases of therapy, HIV-1–specific
CTLps became detectable in some patients immediately after
HAART was started and subsequently either remained stable
or diminished up to disappearance after 9 months of successful
therapy. In agreement with the requirement of relatively con-
served T cell function to detect circulating CTLps in our assay,
as extensively reported by us [22], no HIV-1–specific CTL ac-
tivity was detected in the patients included in the NUCB2019
study before HAART was begun. The disappearance of HIV-
1–specific CTLs during HAART has been elegantly demon-
strated by direct staining with HLA/peptide tetrameric com-
plexes, a technique that does not imply T cell responsiveness
[35, 36]. In our study, a similar pattern of the disappearance
of functionally detectable CTLps was seen in 2 patients,
whereas 4 other patients, once CTLs became detectable during
HAART, maintained stable CTLp frequencies. This discrep-
ancy may reflect the less profund and persistent viral load re-
duction achieved in the latter patients, with residual viral rep-
lication occasionally detected in the assay employed. However,
in 1 case of partial therapy failure associated with the emergence
of drug-resistant viruses, CTLp frequencies progressively in-
creased, together with viral load. This finding confirms the re-
covered lymphocyte capacity to respond to antigenic stimuli,
although it poses the question of what the participation and
efficiency of HIV-1–specific CTLs are in containing viral rep-
lication. Similar results have been recently reported by Dalod
et al., measuring CTL activity in bulk cultures of lymphocytes
stimulated with autologous activated lymphoblasts [37]. In their
patient group, the two patterns of either stable CTL detection
or disappearance during therapy were related either to persist-
ent residual viral load or to complete shutdown of viral rep-
lication, respectively.
In contrast to variably detectable HIV-1–specific CTLs,
CD41 T cells proliferating in response to p24 remained unde-
tectable in patients treated with HAART late in HIV-1 infec-
tion. The finding of vigorous p24-specific LPRs in subjects un-
dergoing HAART starting from symptomatic acute HIV-1
infection was greatly emphasized [38]. We cannot conclude at
this stage that similar responses can never be achieved during
treated advanced infection, but the virtual absence of antigen
associated with viral load suppression argues against this pos-
sibility. The discrepancy between LPRs to recall Ags and HIV-
1 p24 suggests that p24-specific CD41 T memory cells either
are not generated or are deleted during infection. Because re-
circulation from lymphoid tissue is a dominant mechanism of
early T cell number increase during therapy, we can at least
conclude that these cells are not compartmentalized in sites of
viral replication in patients with long-standing infection. Sim-
ilar data, extended also to HIV-1–Env–specific T cells, have
been recently reported by Plana et al. [39], confirming the dis-
cordant behavior of LPRs to microbial Ags (CMV) and HIV-
1 Ags. However, the persistent detection of p17-specific LPRs
in some patients suggests that HIV-1–specific CD41 T cells can
be recruited during HAART, either because of regained func-
tion of previously primed and undeleted lymphocytes or by de
novo priming, given the favorable conditions established during
therapy. LPR to p17 was undetectable in a small group of
asymptomatic HIV-1–infected patients with relatively preserved
T cell function [17], but the existing knowledge on this issue is
limited, and it is currently difficult to establish whether it has
any relevance for the clinical outcome. The apparent paucity
of HIV-1–specific CD41 T cells may result in poor help for
CTLs and their progressive disappearance [36]. It has been sug-
gested that infected dendritic cells may provide activation
signals for CD81 T cells in the absence of CD41 T cell cross-
priming [40], a mechanism that could explain the vigorous ex-
pansion of HIV-1–specific CTLs during untreated HIV-1 in-
fection [21, 22]. During HAART, infection of dendritic cells is
likely to be prevented and CTL stimulation does not occur, as
no significant CD41 T cell help is available. In contrast, when
HAART is administered before seroconversion, prevention of
dendrititc cell infection may allow the presentation of uninfec-
tious Ags able to prime CD41 T cells, [38] which are spared
from subsequent infection.
In conclusion, our results suggest that HAART during ad-
vanced HIV-1 infection induces a partial regaining of T cell
competence with no evidence of repertoire regeneration, which
may occur at later times. This opens the possibility of active
immunizations to optimize protection against infections.
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